AR066354A1 - La terapia sistematica con factor-1 de crecimiento de tipo insulina reduce la neuropatia periferica diabetica y mejora la funcion renal en la nefropatia diabetica - Google Patents
La terapia sistematica con factor-1 de crecimiento de tipo insulina reduce la neuropatia periferica diabetica y mejora la funcion renal en la nefropatia diabeticaInfo
- Publication number
- AR066354A1 AR066354A1 ARP080101822A ARP080101822A AR066354A1 AR 066354 A1 AR066354 A1 AR 066354A1 AR P080101822 A ARP080101822 A AR P080101822A AR P080101822 A ARP080101822 A AR P080101822A AR 066354 A1 AR066354 A1 AR 066354A1
- Authority
- AR
- Argentina
- Prior art keywords
- igf
- diabetic
- treatment
- hyposensitivity
- improves
- Prior art date
Links
- 208000032131 Diabetic Neuropathies Diseases 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 230000003907 kidney function Effects 0.000 title abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
- 102000004877 Insulin Human genes 0.000 title 1
- 108090001061 Insulin Proteins 0.000 title 1
- 229940125396 insulin Drugs 0.000 title 1
- 230000009897 systematic effect Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000004454 Hyperalgesia Diseases 0.000 abstract 2
- 208000035154 Hyperesthesia Diseases 0.000 abstract 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 2
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 210000003205 muscle Anatomy 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 108010071390 Serum Albumin Proteins 0.000 abstract 1
- 102000007562 Serum Albumin Human genes 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 230000036541 health Effects 0.000 abstract 1
- 230000003345 hyperglycaemic effect Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- 230000007659 motor function Effects 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 abstract 1
- 238000009163 protein therapy Methods 0.000 abstract 1
- 230000001953 sensory effect Effects 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Métodos de tratamiento de pacientes que sufren de complicaciones de trastornos de azucar en sangre: neuropatía periférica diabética y nefropatía diabética mediante administracion de IGF-1 mediante terapia proteínica o terapia génica. Se refiere amétodos de tratamiento de un individuo que tiene un trastorno diabético o un trastorno hiperglicémico, que comprende administrar al individuo una cantidad efectiva de un vector de ADN que expresa IGF-1Eb o IGF-1Ec in vivo o una cantidad efectiva dela proteína IGF-1Eb o IGF-1Ec en el estadio temprano de hiperalgesia o en pacientes que han avanzado al estadio de hiposensibilidad. El tratamiento en el estadío temprano de hiperalgesia previene la subsiguiente hiposensibilidad con incrementos omantenimiento de la funcion nerviosa sensorial. El tratamiento con IGF-1Eb o IGF-1Ec también aumenta la masa muscular y mejora la movilidad global, lo que indica una mejora relacionada con el tratamiento en la funcion motora. El tratamiento con IGF-1Eb o IGF-1Ec en el estadio de hiposensibilidad revierte la hiposensibilidad y mejora la masa muscular y la salud global. La IGF-1 sistémica provee una modalidad terapéutica para tratar la hiposensibilidad asociada con DPN. Además, la IGF-1Eb o IGF-1Ec provee una modalidad terapéutica para tratar nefropatía diabética. La IGF-1Eb o IGF-1Ec mejora la funcion renal como se evidencia mediante una modulacion en la concentracion de albumina en suero y una reduccion del volumen de orina y niveles deproteína. La IGF-1Eb o IGF-1Ec también reduce la glomeruloesclerosis diabética.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92724407P | 2007-05-01 | 2007-05-01 | |
| US98921307P | 2007-11-20 | 2007-11-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066354A1 true AR066354A1 (es) | 2009-08-12 |
Family
ID=39944198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101822A AR066354A1 (es) | 2007-05-01 | 2008-04-30 | La terapia sistematica con factor-1 de crecimiento de tipo insulina reduce la neuropatia periferica diabetica y mejora la funcion renal en la nefropatia diabetica |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20100216709A1 (es) |
| AR (1) | AR066354A1 (es) |
| WO (1) | WO2008137490A2 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7239912B2 (en) | 2002-03-22 | 2007-07-03 | Leptos Biomedical, Inc. | Electric modulation of sympathetic nervous system |
| US20090259279A1 (en) * | 2002-03-22 | 2009-10-15 | Dobak Iii John D | Splanchnic nerve stimulation for treatment of obesity |
| US7937145B2 (en) * | 2002-03-22 | 2011-05-03 | Advanced Neuromodulation Systems, Inc. | Dynamic nerve stimulation employing frequency modulation |
| WO2008028037A2 (en) * | 2006-08-30 | 2008-03-06 | Andrew Young | Distender device and method for treatment of obesity and metabolic and other diseases |
| US20090118777A1 (en) * | 2007-08-09 | 2009-05-07 | Kobi Iki | Efferent and afferent splanchnic nerve stimulation |
| WO2010109053A1 (es) * | 2009-03-27 | 2010-09-30 | Proyeto De Biomedicina Cima, S.L. | Métodos y composiciones para el tratamiento de cirrosis y fibrosis hepática |
| US8321030B2 (en) | 2009-04-20 | 2012-11-27 | Advanced Neuromodulation Systems, Inc. | Esophageal activity modulated obesity therapy |
| US8340772B2 (en) | 2009-05-08 | 2012-12-25 | Advanced Neuromodulation Systems, Inc. | Brown adipose tissue utilization through neuromodulation |
| US20140045923A1 (en) * | 2009-07-10 | 2014-02-13 | Universidad Autónoma De Barcelona | Gene therapy compositions for preventing and/or treating of autoimmune diseases |
| CA3128549A1 (en) | 2010-07-12 | 2012-01-19 | Universitat Autonoma De Barcelona | Gene therapy composition for use in diabetes treatment |
| AU2012210013C1 (en) | 2011-01-26 | 2017-06-01 | Megmilk Snow Brand Co., Ltd. | Sense-improving agent |
| EP2692868A1 (en) | 2012-08-02 | 2014-02-05 | Universitat Autònoma De Barcelona | Adeno-associated viral (AAV) vectors useful for transducing adipose tissue |
| EP3194430A1 (en) | 2014-09-16 | 2017-07-26 | Universitat Autònoma De Barcelona | Adeno-associated viral vectors for the gene therapy of metabolic diseases |
| ES2824457T3 (es) * | 2014-12-05 | 2021-05-12 | UNIV AUTòNOMA DE BARCELONA | Vectores virales para el tratamiento de la diabetes |
| CA2970539A1 (en) * | 2014-12-16 | 2016-06-23 | Puretein Bioscience Llc. | Methods for increasing serum igf-1 in an animal |
| EP3978614A3 (en) | 2015-01-07 | 2022-07-27 | Universitat Autònoma de Barcelona | Single-vector gene construct comprising insulin and glucokinase genes |
| MX2019000962A (es) | 2016-07-26 | 2019-08-01 | Biomarin Pharm Inc | Novedosas proteinas de la capside del virus adenoasociado. |
| AU2019265560A1 (en) * | 2018-05-09 | 2020-11-26 | Biomarin Pharmaceutical Inc. | Methods of treating phenylketonuria |
| TW202005978A (zh) | 2018-05-14 | 2020-02-01 | 美商拜奧馬林製藥公司 | 新穎肝靶向腺相關病毒載體 |
| JP7413629B2 (ja) * | 2018-07-17 | 2024-01-16 | ヘリックスミス カンパニー， リミテッド | Ｉｇｆ－１異型体を発現させるｄｎａコンストラクトを用いた神経病症の治療 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5948757A (en) * | 1996-03-01 | 1999-09-07 | Celtrix Pharmaceuticals, Inc. | High dose IGF-1 therapy |
| WO1997039789A1 (en) * | 1996-04-22 | 1997-10-30 | Medtronic, Inc. | Two-stage angled venous cannula |
| GB9926968D0 (en) * | 1999-11-15 | 2000-01-12 | Univ London | Treatment of neurological disorders |
| SE0101934D0 (sv) * | 2001-06-01 | 2001-06-01 | Pharmacia Ab | New methods |
| AU2002364221B2 (en) * | 2001-12-21 | 2008-07-10 | The Salk Institute For Biological Studies | Targeted retrograde gene delivery to motor neurons |
-
2008
- 2008-04-30 AR ARP080101822A patent/AR066354A1/es unknown
- 2008-05-01 WO PCT/US2008/062129 patent/WO2008137490A2/en active Application Filing
-
2009
- 2009-10-30 US US12/609,115 patent/US20100216709A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008137490A2 (en) | 2008-11-13 |
| US20100216709A1 (en) | 2010-08-26 |
| WO2008137490A3 (en) | 2008-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066354A1 (es) | La terapia sistematica con factor-1 de crecimiento de tipo insulina reduce la neuropatia periferica diabetica y mejora la funcion renal en la nefropatia diabetica | |
| Hellsten et al. | Passive leg movement enhances interstitial VEGF protein, endothelial cell proliferation, and eNOS mRNA content in human skeletal muscle | |
| ATE479458T1 (de) | Medizinisches system für infusion | |
| Mafauzy et al. | DiabCare 2013: A cross-sectional study of hospital based diabetes care delivery and prevention of diabetes related complications in Malaysia | |
| Shree et al. | Can yoga therapy stimulate stem cell trafficking from bone marrow? | |
| Korabiewska et al. | Need for rehabilitation in renal replacement therapy involving allogeneic kidney transplantation | |
| WO2007002571A3 (en) | Use of an anti c5 complement antibody to treat patients with sickle cell disease | |
| Kakanos et al. | Delayed peripheral treatment with neurotrophin-3 improves sensorimotor recovery after central nervous system injury | |
| Amirova | FUNCTIONAL FOODS WITH HYPOGLYCEMIC HERBS FOR DIABETES MILLITUS | |
| Król et al. | Obesity in patients with end-stage heart failure | |
| Harpham | View From the Other Side of the Stethoscope: Patient Handout: Walking with Hope During Cancer Treatment | |
| Vanelli et al. | Faith/spiritual healing/therapeutic prayer | |
| Baranello et al. | P. 360Body composition predicts clinical response in SMA patients treated with nusinersen | |
| Aksenova et al. | An association between the FABP2 gene polymorphism and efficacy of valproates | |
| RU2402325C1 (ru) | Способ лечения нейрососудистых осложнений сахарного диабета | |
| Jalota | Metabolic syndrome: case report | |
| UA50725U (ru) | Способ лечения больных с прогрессирующей мышечной дистрофией трансплантацией миобластов эмбриона человека | |
| Pankiv | Modern possibilities of correction functional State of the liver in patients diabetes using medication Hepa-Merz (L-ornithine-L-aspartate) | |
| TW202131887A (zh) | 一種促進脊髓動物內臟運動、細胞新生活化機能、以增進萬能抗體驅離解離攻退各種抗原、使***至體外的方法 | |
| Kalidindi | Acute kidney injury and diabetic ketoacidosis: case report | |
| Gumeniuk | The principles of preventive and treatment use of the preformed physical factors at arterial hypertension | |
| Chernyshev et al. | Diagnosis and treatment of metabolic syndrome in health centres | |
| Kornetov et al. | OVERWEIGHT AND OBESITY IS MODERN PROBLEMS IN DEPRESSIVE DISORDERS | |
| Motamed | Orolingual angioedema: 2 case reports | |
| Serebrennikova et al. | The features of collective and personal stressful psychotherapy of hysterical neurosis, hysteria, hysterical psychopathology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |